Insulin resistance can improve, and for many people, the biggest gains come from changes that make the body more responsive to insulin. The strongest evidence supports two approaches in particular: losing excess body fat when it is contributing to insulin resistance and increasing physical activity (Dubé et al. 2022, Colberg et al. 2016). Exercise can improve insulin sensitivity even when the number on the scale does not change. Sleep, prescription medications, and other approaches may help too, although the evidence for them is often more limited or measures a different outcome.
That distinction matters because studies do not all ask the same question. Some measure insulin sensitivity directly, while others look at blood sugar, the risk of developing type 2 diabetes, or whether diabetes goes into remission. Those findings are related, but they are not interchangeable. There is also no permanent “cure” or universal timeline for reversing insulin resistance. Improvements tend to last as long as the changes producing them are maintained, and they may fade if those changes stop.
What the evidence actually supports
In research terms, “reversing” insulin resistance means one thing: a measurable improvement in how responsive your tissues are to insulin. It does not mean a permanent state change, and it does not mean insulin resistance cannot return. Studies that measure this directly use methods such as the hyperinsulinemic-euglycemic clamp, which quantifies how much glucose the body takes up at a given insulin level.
The most direct evidence comes from controlled weight-loss studies in adults with obesity, where insulin sensitivity was measured in adipose tissue, liver, and muscle before and after weight change (Magkos et al. 2016). Next is physical activity, where the effect of a single exercise bout on insulin-stimulated glucose uptake has been characterized in detail, including in insulin-resistant muscle (Cartee 2015). Sleep evidence exists but is narrower, resting on small short-term experiments. Medication and supplement evidence requires close attention to who was studied and what outcome was recorded.
Improving insulin sensitivity, reducing the number of people who go on to develop type 2 diabetes, and achieving remission of established type 2 diabetes are three different outcomes measured in three different ways. Prevention data cannot be used to prove reversal unless insulin sensitivity was directly measured.
Weight change
For people with overweight or obesity, weight loss is among the best-supported ways to improve insulin sensitivity. It is not, however, relevant to everyone who has been told they are insulin resistant.
The most direct evidence comes from a randomized controlled study in adults with obesity in which insulin sensitivity was measured directly at multiple tissues. Approximately 5% weight loss improved insulin sensitivity in adipose tissue, the liver, and skeletal muscle, and further weight loss produced additional improvements in some, though not all, measured outcomes (Magkos et al. 2016). The important point is what was measured: insulin sensitivity itself. The specific amounts of weight lost in that trial were study results, not targets set for readers.
The Diabetes Prevention Program (DPP) is a different kind of evidence and answers a different question. It enrolled 3,234 adults with impaired glucose regulation who were at high risk for type 2 diabetes, and randomized them to an intensive lifestyle intervention with a study target of at least 7% weight loss plus at least 150 minutes per week of physical activity, to metformin, or to placebo (Knowler et al. 2002). Those targets and the study medication are trial design details, not personal recommendations.
Over a mean of 2.8 years, the lifestyle intervention reduced the number of participants who developed type 2 diabetes by 58%, and metformin reduced it by 31%, compared with placebo (Knowler et al. 2002). That is an incidence outcome: fewer people crossing the diagnostic threshold, not a 58% improvement in insulin resistance. The effect also changed over time. At 10 years, the reductions in diabetes incidence were 34% and 18% (DPP Research Group 2009). At 15 years, they were 27% and 18%, with cumulative diabetes incidence of 55% in the lifestyle group, 56% in the metformin group, and 62% in placebo; aggregate microvascular outcomes did not differ significantly between groups at that point (DPP Research Group 2015). Read together, these results support delay and reduced incidence, not a persistent 58% effect on insulin resistance. Current NIDDK materials describing the program’s public-health translation reference 5%–7% weight loss, which is guidance rather than the original trial target (NIDDK DPP). Finally, insulin resistance also occurs in people who are not overweight or obese, so weight loss is not a universal answer.
If you are trying to understand where your own insulin resistance came from, see insulin resistance causes, and for how food patterns fit into the wider picture, see insulin resistance and diet.
Physical activity
Physical activity can improve insulin sensitivity after a single session, independently of weight loss. That is one of the more useful facts in this field, and it is frequently misdescribed.
Two separate mechanisms are involved. During exercise and for a short period afterward, muscle contraction itself increases glucose uptake without requiring insulin. That contraction-mediated uptake is largely reversed by roughly 2–3 hours after exercise ends (Cartee 2015). Separately, and this is the part that matters for insulin resistance, the same exercise enhances insulin-stimulated glucose uptake in skeletal muscle and whole-body insulin sensitivity afterward.
This enhanced insulin sensitivity can persist for roughly 24–48 hours following a single session, and it has been demonstrated in insulin-resistant muscle as well as normal muscle (Cartee 2015). The distinction between contraction-mediated uptake and post-exercise insulin sensitization has been described in the exercise physiology literature for decades (Richter & Hargreaves 2013).
This is a temporary, repeatable effect measured after one bout of exercise and not evidence that insulin resistance is reversed within 48 hours. Because the window closes, the effect depends on repetition rather than on any single session. Beyond that, the research does not support quoting a specific percentage improvement, and this article does not prescribe how long, how often, or how hard to exercise. That is a conversation for your clinician.
Sleep
Sleep can affect insulin sensitivity, but the direct experimental evidence is narrow and points one way. In a randomized crossover trial in postmenopausal women, four nights of sleep restriction reduced clamp-measured insulin sensitivity compared with their usual sleep; 14 participants were enrolled, and nine were included in the analysis.
Under low-dose insulin infusion, the glucose infusion rate (how much glucose the body cleared at a given insulin level) was 20% lower after restriction, and under high-dose infusion it was 12% lower (Singh et al. 2023). That establishes short-term harm from restricted sleep in a small, specific population. It is not evidence that extending sleep beyond your habitual amount produces an equal and opposite improvement, and it says nothing about a specific number of hours you should sleep.
Medication
No medication is approved by the FDA specifically for the treatment of insulin resistance as a standalone condition (Freeman et al., StatPearls). This is a frequent source of confusion, because several widely used drugs do affect metabolic outcomes and may affect insulin sensitivity. They are simply approved for other indications.
Metformin is the clearest example. Its current U.S. prescribing information indicates it as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus (DailyMed metformin label). That is a blood-glucose-control indication in diagnosed type 2 diabetes, not an insulin-resistance indication.
The most-cited metformin finding in this area comes from the DPP, where metformin reduced progression to type 2 diabetes by 31% over a mean of 2.8 years in adults at high risk because of impaired glucose regulation (Knowler et al. 2002). Again, that is an incidence outcome in a high-risk population (fewer people developing diabetes over a defined period). It is not a direct measurement showing that insulin resistance was reversed. Newer glucose-lowering and weight-management medications raise related questions, which are discussed in the next section. Decisions about any prescription medication belong to a clinical conversation about your own situation, and this article makes no recommendation about any of them.
What has held up, what hasn’t, and what remains disputed
Held up. Three findings have proved durable, with their populations attached. Weight loss can directly improve insulin sensitivity in people with obesity, as measured at the level of adipose tissue, liver, and muscle in a randomized controlled study (Magkos et al. 2016). A single bout of exercise can enhance insulin-stimulated glucose uptake afterward, including in insulin-resistant skeletal muscle, and the effect can be repeated (Cartee 2015). Short-term sleep restriction can impair clamp-measured insulin sensitivity, demonstrated in a small randomized crossover trial in postmenopausal women (Singh et al. 2023). The breadth of these evidence bases differs considerably, which is why the populations matter.
Hasn’t held up, or hasn’t yet. The staged reversal timelines that circulate online (something happens in week one, more by month one, “reversal” by three or six months) are not supported by the studies used to justify them. The 24–48-hour figure frequently cited describes how long enhanced insulin sensitivity persists after a single exercise session (Cartee 2015). The DPP’s roughly 3-, 10-, and 15-year follow-up periods describe how many people developed type 2 diabetes over time, not how long insulin resistance takes to resolve.
Supplements. Berberine and chromium are the two most discussed, and most of the research has been conducted in people with established type 2 diabetes. NCCIH characterizes the overall evidence as limited, weak, and heterogeneous, and neither is established as a treatment for insulin resistance (NCCIH diabetes & supplements).
Disputed. An open question is how much newer incretin-based medications improve insulin sensitivity through weight loss versus through effects not fully explained by weight loss. One exploratory post hoc analysis of a 28-week randomized trial in people with type 2 diabetes who were taking metformin compared tirzepatide, semaglutide, and placebo using clamp and Matsuda-index measures of insulin sensitivity, and reported greater improvement in insulin sensitivity per unit of weight lost with tirzepatide than with semaglutide (Mather et al. 2025). The analysis was funded by Eli Lilly and Company, which makes tirzepatide. Because the analysis was exploratory and post hoc, and because the population was people with established type 2 diabetes on metformin, it raises the question rather than settling it. It is not proof of a weight-independent class effect.
Frequently asked questions
Do supplements help with insulin resistance?
There is no strong evidence that any supplement reliably reverses insulin resistance. Berberine and chromium come up most often, but much of the research was done in people who already have type 2 diabetes, and NCCIH describes the evidence as limited and heterogeneous (NCCIH T2D supplements digest).
For chromium, NCCIH summarizes a 2022 review of 16 studies and 868 participants suggesting improvements in A1C, fasting glucose, and insulin resistance in people with type 2 diabetes, a population that already has the diagnosis, while noting that no clear evidence shows chromium prevents diabetes. For berberine, NCCIH summarizes a 2021 review of 46 studies and 4,158 participants suggesting improvements in glucose, insulin resistance, and lipids in people with type 2 diabetes, with meaningful limitations in study quality and consistency.
How long does it take to reverse insulin resistance?
There is no reliable general timeline, and this is the question where misinformation is most common. Studies measure different outcomes in different populations, so their durations are not interchangeable. The 24–48-hour figure frequently cited describes how long enhanced insulin sensitivity persists after a single exercise session (Cartee 2015). It is a short-term post-bout window, not evidence that insulin resistance resolves in two days.
Can you improve insulin resistance without losing weight?
Yes. Physical activity is the clearest example: a single exercise session enhances insulin-stimulated glucose uptake and whole-body insulin sensitivity afterward, independently of any weight loss, and this has been shown in insulin-resistant muscle as well (Cartee 2015). Sleep research points the same direction in that insulin sensitivity can change without weight change, though the trial cited here established harm from four nights of restriction rather than benefit from extending sleep (Singh et al. 2023). None of this means weight change is unimportant when excess adiposity is part of the picture; where it is relevant, it carries the most direct evidence (Magkos et al. 2016).
Does insulin resistance come back if you stop?
At least some improvements depend on continued exposure. The enhancement in insulin sensitivity after a single exercise bout is transient, persisting roughly 24–48 hours (Cartee 2015). That shows the effect follows the behavior. That does not mean every improvement disappears on a fixed schedule. Changes associated with weight loss may persist while the weight loss is maintained (Magkos et al. 2016), and in long-term DPP follow-up the reduction in diabetes incidence attenuated over 10 and 15 years without simply vanishing (DPP 2009, DPP 2015). The more accurate framing is that insulin sensitivity is dynamic rather than a permanent, one-time state.
Is metformin used to treat insulin resistance?
Metformin is sometimes studied or used in clinical situations where insulin resistance is relevant, but it is not FDA-approved specifically for insulin resistance as a standalone condition; no medication is (Freeman et al., StatPearls). Its U.S. labeled indication is to improve glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes mellitus, as an adjunct to diet and exercise (DailyMed). In the DPP, metformin reduced progression to type 2 diabetes by 31% over a mean of 2.8 years in adults with impaired glucose regulation (Knowler et al. 2002). That is a diabetes-incidence result in a high-risk population, which does not by itself demonstrate that insulin resistance was reversed.
Conclusion
Insulin sensitivity can improve, and that is a meaningful, measurable thing. The evidence is strongest for weight change where excess adiposity is part of the picture, and for physical activity, which acts even without weight loss.
Sleep appears to matter, but the direct experimental base is narrow. Medications and supplements require careful attention to who was studied and what was measured: diabetes incidence, blood glucose control, and insulin sensitivity are distinct outcomes. No intervention is a permanent, one-time fix, and there is no universal timeline for reversal.
References
- Magkos F, Fraterrigo G, Yoshino J, et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016;23(4):591-601. doi:10.1016/j.cmet.2016.02.005
- Cartee GD. Mechanisms for greater insulin-stimulated glucose uptake in normal and insulin-resistant skeletal muscle after acute exercise. Am J Physiol Endocrinol Metab. 2015;309(12). doi:10.1152/ajpendo.00416.2015
- Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512
- Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686. doi:10.1016/S0140-6736(09)61457-4
- Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up. Lancet Diabetes Endocrinol. 2015;3(11):866-875. doi:10.1016/S2213-8587(15)00291-0
- National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Prevention Program (DPP).
- Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013;93(3):993-1017. doi:10.1152/physrev.00038.2012
- Singh P, Beyl RA, Stephens JM, et al. Effect of sleep restriction on insulin sensitivity and energy metabolism in postmenopausal women: A randomized crossover trial. Obesity (Silver Spring). 2023;31(5):1204-1215. doi:10.1002/oby.23739
- Freeman AM, Acevedo LA, Pennings N. Insulin Resistance. StatPearls. Treasure Island (FL): StatPearls Publishing; updated Aug 17, 2023.
- National Library of Medicine. Metformin hydrochloride tablets, USP: Prescribing Information. DailyMed.
- National Center for Complementary and Integrative Health. Diabetes and Dietary Supplements: What You Need To Know.
- Mather KJ, Mari A, Weerakkody G, et al. Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis. Diabetes Obes Metab. 2025;27(3):1507-1514. doi:10.1111/dom.16159
- National Center for Complementary and Integrative Health. Type 2 Diabetes and Dietary Supplements. NCCIH Clinical Digest. November 2022.